SITC 2022
Data Read-out



INVESTOR RELATIONS 2022

NEOIMMUNETECH

November 14, 2022

Disclaimer

This document has been prepared by NeoImmuneTech, Inc. (the "Company") solely for informational purpose as a presentation to investors and is strictly prohibited to be passed on, copied, or redistributed.

By participating in this presentation, the recipient of information hereby acknowledges and agrees to comply with the aforementioned restrictions, and such violations are subject to a violation of the Capital Market and Financial Investment Act. Projections contained in this document have not been subjected to individual verifiers. They are predictions of future, not past, events. This document explains the Company's anticipated business and financial performance, and includes expressions such as "anticipation", "forecast", "plan", "expectation", and "(E)".

The aforementioned "forecasted information" is influenced by future changes in the business environment and by definition contain uncertainties. Due to this inherent uncertainty, actual performance in the future may differ from what is stated or implied in the "forecasted information" presented in this document. Moreover, future forecasts in this presentation have been prepared given the current market situation and the Company's management direction and is subject to change depending on changes in either the market situation or strategy. The information presented or contained in these materials is subject to change without notice.

We are not responsible for any losses incurred in connection with the use of this material, including negligence or otherwise, by our employees. This document does not constitute solicitation for the recruitment, sale, or subscription of shares and no part of the document shall constitute an invitation to relevant contracts and arrangements or investment decisions.

Poster Presentation at

1. **NIT-110 biomarker data (Ph.2a) oral presentation, Poster 657**
   - CPI naïve MSS-CRC and PaC
2. **NIT-107 newly diagnosed GBM (Ph.1) Poster 624**
3. **Other posters**
   - **NIT-115 squamous cell carcinoma of head and neck (Ph.1 Protocol) Poster 679**
   - **T cell engager combo (Preclinical) Poster 837**
   - **Skin cancer (Preclinical) Poster 849**

NEOIMMUNETECH

Key Messages for NIT-110

Pembrolizumab plus NT-I7 shows significant clinical efficacy in CPI-naïve r/r MSS-CRC and PaC in the absence of liver metastasis

1. **Pembrolizumab plus NT-I7 shows remarkable efficacy in immunologically cold CPI-naïve r/r MSS-CRC and PaC in the absence of liver metastasis**
2. **Patients without liver metastasis have higher objective response rate and disease control rates (ORR=30.8%; DCR=69.2%; per iRECIST)**
3. **$CD8^+$ T cell infiltration is increased in patients regardless of liver metastasis and correlates with higher overall survival**

* Data cutoff date April 29, 2022

Higher efficacy in patients without liver metastasis

- Patients without liver metastasis have higher objective response rate (ORR, 30.8%) and disease control rates (DCR, 69.2%) per iRECIST
- Patients with liver metastasis still showed clinical benefit (1 patient with 3 liver lesions had a partial response per iRECIST with 46% tumor reduction, and DCR was 25.6%)



* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

	ORR [% (n/total n)]		DCR [% (n/total n)]	
	RECIST v1.1	iRECIST	RECIST v1.1	iRECIST
NO liver metastasis (n=13)	**15.4% (2/13)**	**30.8% (4/13)**	**53.9% (7/13)**	**69.2% (9/13)**
YES liver metastasis (n=37)	0.0% (0/37)	2.7% (1/37)	21.6% (8/37)	24.3% (9/37)

Historical ORR with anti-PD(L)1 monotherapy in these indications is 0%[1-2]

[1] KEYNOTE-016. Le DT et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency (2015) N Engl J Med
[2] O'Reilly et al., Durvalamab with or without Tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma (2019) JAMA Oncol

Liver metastasis impacts overall survival

- Patients without liver metastasis showed significantly higher overall survival
- Among the patients without liver metastasis, the probability of survival rate through 60 weeks (approx. 15months) was 100% , which is significantly higher than in those with liver metastasis



* $p<0.05$

mOS of SoC for MSS-CRC and PaC

- mOS of SoC for MSS-CRC (3L+) and PaC (2L+) treatments is 7.1 months at best

Treatment	MSS-CRC (3L+)
Lonsurf	mOS: 7.1 months
Stivarga	mOS: 6.4 months
*Lonsurf + Avastin	9.4 months
*Fruquintinib	7.4 months

Treatment	PaC (2L+)
Onivyde	6.1 months
*Gemcitabine + Nab-paclitaxel	7.1 months
*5-FU + Leucovorin + Oxaliplatin (mFOLFOX6)	5.9 months

Source: FDA label
*Considerable use of medicines for off-label
*SoC data was updated (Jan. 2023)

Increased CD8+ TIL regardless of liver metastasis

- CD8+ TIL is significantly increased in patients both with and without liver metastasis after Pembrolizumab + NT-I7 combo



Fold Change TIL density [POST:PRE]	
All patients	4.44X
NO liver metastasis (n = 4)	**9.22X**
YES liver metastasis (n = 15)	**3.17X**



* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

* TIL: Tumor Infiltrating Lymphocytes

Appendix: NIT-110 study protocol

- CPI-naïve r/r solid tumors
- Pembrolizumab IV (Q3W; 200 mg) + NT-I7 IM (Q6W; 1,200 μg/kg)





Primary Objectives

- ORR (Objective Response Rate)

Key Messages for NIT-107

NT-I7 added to standard of care chemoradiotherapy in patients with high-grade gliomas is well tolerated

1. **CCRT+NT-I7 combo showed promising mOS and mPFS in overall GBM patients**

SoC+NT-I7 combo		SoC (CCRT)	
mPFS 13.7 M	mOS 19.1 M	mPFS 6.8 M	mOS 15 M

2. **Significant clinical benefit is shown especially in MGMT unmethylated GBM, which is harder to treat than methlylated GBM**

SoC+NT-I7 combo		SoC (CCRT)	
mPFS 11.2 M	mOS 15.9 M	mPFS 5.2 M	mOS 12.4 M

* Data cutoff date July 15, 2022

mPFS and mOS in patients with GBM

- NT-I7 after completion of radiotherapy and temozolomide demonstrated sustained improvements in mPFS and mOS

All GBM patients





MGMT unmethylated patients





MGMT methylated patients





CCRT+NT-I7 combo improves mPFS, mOS

- CCRT+NT-I7 combo showed promising mPFS and mOS in overall GBM patients
- Significant clinical benefit is shown especially in MGMT unmethylated GBM patients
- MGMT unmethylated GBM patients is a sub-group who often have a poorer prognosis

Type	SoC (CCRT)[1-11]		SoC + NT-I7	
	Median PFS	Median OS	Median PFS	Median OS
Overall GBM	6.8 month (6.2 – 7.3)	15.0 month (12.5 – 16.7)	13.7 month (9.5 – 20.3)	19.1 month (14.9 – 22.0)
GBM with methylated MGMT	9.5 month (7.5 – 10.7)	22.3 month (18.9 – 26.3)	19.1 month (15.1 – NR)	21.9 month (20.7 – NR)
GBM with unmethylated MGMT	5.2 month (4.1 – 6.3)	12.4 month (11.1 – 13.4)	11.2 month (5.4 – 22.4)	15.9 month (12.3 – 24.3)

[1]Hegi et al., 2005 [2]Weller et al., 2009 [3]Stupp et al., 2005 [4]Stupp et al., 2009 [5]Stupp et al., 2014
[6]Gilbert et al., 2014 [7]Chinot et al., 2015 [8]Nabers et al., 2015 [9]Fabbro-Peray et al., 2019 [10]Annavarapu et al., 2021
*SoC data was updated (Jan. 2023)

Appendix: NIT-107 study protocol

- Targeted newly diagnosed GBM patients
- Surgery → SoC (Chemo/Radiation) + NT-I7 Injection (Q12W, 4 times)
- Ph.1b/2a: Currently in dose escalation (1b) → Dose expansion (2a)



DL	NT-I7
1	60 μg/kg
2	120 μg/kg
3	240 μg/kg
4	540 μg/kg
5	720 μg/kg
6	960 μg/kg

NT-I7 development status

- After PoC is demonstrated from ph.1b/2a studies, a pivotal study design will be prepared



1. ALC: AACR 2018, AACR 2019, SITC 2019, ASCO 2020, SITC 2020, ASCO 2021, SNO 2021, ITC 2021, AACR 2022, Kim JH et al. Clinical & Translational Immunology; e1168 (2020), Campian JL. et al. Clin Cancer Res. 2022 Mar 15;28(6):1229-1239.
2. Tscm: SITC 2021, ASCO 2022
3. TIL: ASCO 2021, SITC 2021, ESMO GI 2022, Kim JH et al. Clinical & Translational Immunology; e1168 (2020)
4. Tpex: AACR 2022

Major events in 2023

	1H 2023	2H 2023
Data Read-outs	▪ NIT-110: Solid tumor, CPI Combo Ph.2a interim	▪ NIT-110: Solid tumor, CPI Combo Ph.2a final ▪ NIT-107: GBM, CCRT Combo Ph.1/2 ▪ NIT-119: 1L NSCLC, CPI Combo Ph.2 ▪ NIT-106: Skin cancer, CPI Combo Ph.2 ▪ NIT-109: Gastric cancer, CPI Combo Ph.1 ▪ NIT-112: LBCL, CAR-T Combo Ph.1b final

* Plans are subject to change

NEOIMMUNETECH

THANK YOU

[Inquiry] ir@neoimmunetech.com